ImmunityBio (IBRX) Cash from Investing Activities (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Cash from Investing Activities data on file, last reported at -$31.6 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 866.53% year-over-year to -$31.6 million in Q1 2026; TTM through Mar 2026 was -$185.6 million, a 774.71% decrease from a year earlier, with the FY2025 full-year figure at -$149.8 million, down 1123.26% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$31.6 million, down from $43.6 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for IBRX reached as high as $116.7 million in Q2 2022 and fell as low as -$181.4 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$11.6 million across 5 years, with a median of -$8.6 million in 2023.
• Across the five-year window, Cash from Investing Activities jumped 1012.33% in 2022 and sank 1238.27% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at -$18.9 million in 2022, then soared by 111.9% to $2.2 million in 2023, then soared by 337.26% to $9.8 million in 2024, then jumped by 343.09% to $43.6 million in 2025, then plunged by 172.64% to -$31.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$31.6 million in Q1 2026, $43.6 million in Q4 2025, and -$181.4 million in Q3 2025.